. 2021 Mar 12;16(3):e0248427. doi: 10.1371/journal.pone.0248427

Table 2. H. pylori status in IBD patients and controls.

	H. pylori prevalence	X²	p	OR (CI 95%)
CD	8.9% (19/213)	33.927	5.723*10⁻⁹	0.236
controls	29.3% (125/426)	33.927	5.723*10⁻⁹	(0.141–0.395)
UC	12.8% (6/47)	6.043	0.014	0.312
controls	31.9% (30/94)	6.043	0.014	(0.120–0.816)
IBD	9.6% (25/260)	39.813	2.796*10⁻¹⁰	0.251
controls	29.8% (155/520)	39.813	2.796*10⁻¹⁰	(0.159–0.394)
CD naive^*	10.6% (5/47)	5.841	0.016	0.296
Controls	28.7% (27/94)	5.841	0.016	(0.106–0.827)
UC naive^*	15.8% (3/19)	1.629	0.202	0.406
Controls	31.6% (12/38)	1.629	0.202	(0.099–1.664)
IBD naive^*	12.1% (8/66)	7.379	0.007	0.329
controls	29.5% (39/132)	7.379	0.007	(0.144–0.753)

CD: Crohn’s disease, UC: ulcerative colitis; IBD, inflammatory bowel disease; OR: odds ratio; CI: confidence interval.

*: Newly diagnosed patients.